Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
26 3월 2024 - 8:30PM
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage
biotechnology company pioneering the development of a novel class
of oncolytic immunotherapies, today announced changes to its
executive leadership team designed to support the Company’s
preparations for the commercial launch of RP1, pending regulatory
submission and approval in anti-PD1 failed melanoma.
Sushil Patel, Ph.D., will succeed Philip Astley-Sparke as CEO
effective April 1, 2024. Mr. Astley-Sparke will transition from his
current role as CEO to Executive Chairman of the Board of
Directors. Dr. Patel joined Replimune three years ago initially as
Chief Commercial Officer and served most recently as Chief Strategy
Officer. He has more than 20 years of experience in the biotech
industry including pre- and post-launch commercialization strategy
and execution in both the U.S. and global markets. He has been
involved in more than eight product launches in various roles of
increasing responsibility across marketing, sales, and franchise
management. Prior to joining Replimune, Dr. Patel served as
franchise head for lung, skin and rare cancers at Genentech.
“Replimune is preparing to bring its first oncolytic
immunotherapy to patients, and I am incredibly proud to be able to
lead the Company through this next phase of growth as we transition
to a commercial stage company,” said Sushil Patel. “In the near
term, we will be laser focused on delivering on our strategic
priorities, including the anti-PD1 failed melanoma data and
subsequent biologics license application submission, as well as
launching our confirmatory trial in melanoma.”
Additional changes include:
- Robert Coffin, Ph.D., Founder, President and Chief Research
& Development Officer will move to an advisory role as Founder
and Chief Scientist and will continue to serve on the Board of
Directors.
- Paul Bullock is being appointed Chief Manufacturing Officer and
will assume oversight of manufacturing and lead operations in
Framingham and Milton Park in the United Kingdom, following the
retirement of Colin Love, Ph.D., Chief Operations Officer, and
co-founder, who established our manufacturing operations.
- Pamela Esposito, Ph.D., Chief Business Officer, and Tanya
Lewis, Chief Development Operations Officer, will leave their
executive positions and plan to continue to lend their functional
expertise in an advisory capacity.
“In 2015, Philip and I set out on a journey to develop a new
class of oncolytic immunotherapies,” said Robert Coffin, Ph.D.,
Founder, President and Chief Research & Development Officer of
Replimune. “As we now look towards submitting our first BLA and to
future commercialization, the time is right to transition from the
team that founded the company to the one that will take us through
a potential launch and beyond.”
Philip Astley-Sparke, CEO of Replimune continued, “Rob and I are
very grateful for the invaluable contributions made by Colin Love,
who established our state-of-the-art manufacturing capability,
Pamela Esposito for driving our financing efforts and establishing
our industry collaborations and to Tanya Lewis for scaling our
operations. We all remain committed to supporting the company going
forward and are confident that under Sushil’s leadership, Replimune
will be well positioned to realize the promise of oncolytic
immunotherapy across a broad range of indications in skin cancer
and beyond.”
About Replimune Replimune
Group, Inc., headquartered in Woburn, MA, was founded in 2015
with the mission to transform cancer treatment by pioneering the
development of a novel portfolio of oncolytic immunotherapies.
Replimune’s proprietary RPx platform is based on a potent HSV-1
backbone intended to maximize immunogenic cell death and the
induction of a systemic anti-tumor immune response. The RPx
platform is designed to have a unique dual local and systemic
activity consisting of direct selective virus-mediated killing of
the tumor resulting in the release of tumor derived antigens and
altering of the tumor microenvironment to ignite a strong and
durable systemic response. The RPx product candidates are expected
to be synergistic with most established and experimental cancer
treatment modalities, leading to the versatility to be developed
alone or combined with a variety of other treatment options. For
more information, please visit www.replimune.com.
Forward Looking Statements This press
release contains forward looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including
statements regarding our expectations about the design and
advancement of our clinical trials, the timing and sufficiency of
our clinical trial outcomes to support potential approval of any of
our product candidates, our goals to develop and commercialize our
product candidates, patient enrollments in our existing and planned
clinical trials and the timing thereof, and other statements
identified by words such as “could,” “expects,” “intends,” “may,”
“plans,” “potential,” “should,” “will,” “would,” or similar
expressions and the negatives of those terms. Forward-looking
statements are not promises or guarantees of future performance,
and are subject to a variety of risks and uncertainties, many of
which are beyond our control, and which could cause actual results
to differ materially from those contemplated in such
forward-looking statements. These factors include risks related to
our limited operating history, our ability to generate positive
clinical trial results for our product candidates, the costs and
timing of operating our in-house manufacturing facility, the timing
and scope of regulatory approvals, the availability of combination
therapies needed to conduct our clinical trials, changes in laws
and regulations to which we are subject, competitive pressures, our
ability to identify additional product candidates, political and
global macro factors including the impact of the coronavirus as a
global pandemic and related public health issues and the
Russian-Ukrainian and Israel-Hamas political and military
conflicts, and other risks as may be detailed from time to time in
our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q
and other reports we file with the Securities and Exchange
Commission. Our actual results could differ materially from the
results described in or implied by such forward-looking statements.
Forward-looking statements speak only as of the date hereof, and,
except as required by law, we undertake no obligation to update or
revise these forward-looking statements.
Investor InquiriesChris BrinzeyICR
Westwicke339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen
GoldenbergReplimune917.548.1582media@replimune.com
Replimune (NASDAQ:REPL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Replimune (NASDAQ:REPL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024